HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major trend -Technavio

NEW YORK, Aug. 21, 2023 /PRNewswire/ -- The HIV drugs market is estimated to grow by USD 10,477.51 million at a CAGR of 5.46% from 2022 to 2027, according to Technavio- Download a Sample Report

HIV Drugs Market Insights -

• Companies: 15+, Including AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Cadila Pharmaceuticals Ltd., among others
• company landscape; company product insights and recent developments; key companies; and market positioning of companies, market segmentation by distribution channel (offline and online), therapy (combination HIV medicines, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW))

To understand more about the HIV drugs market, request a sample report

HIV drugs market - Company Insights

The growing competition in the market is compelling companies to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market companies including - AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Cadila Pharmaceuticals Ltd.

HIV Drugs Market – Market Dynamics

Key Drivers- The increasing prevalence of HIV aids worldwide is a key factor driving market growth. 

Major Trends- Expanding access to HIV treatment is a major trend in the market. 

Significant Challenges

The increasing drug resistance among individuals is a significant challenge restricting market growth. HIV, with its high mutation rate, can become resistant to the antiretroviral drugs used in treatment. Failure to adhere to prescribed regimens and inconsistent use can cause viral mutations and resistance, which can lead to ineffective antiviral therapy. In addition, drug-resistant strains of HIV can spread to others, increasing health risks. Addressing this problem requires increased investment in healthcare and spending on labs. Hence, increasing drug resistance among individuals is expected to restrict market growth during the forecast period.

Drivers, Trends & Challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report!

The HIV drugs market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as prospects.

Why Buy?

• Add credibility to the strategy
• Analyzes competitor's offerings 
• Get a holistic view of the market
• Grow your profit margin with Technavio- Buy the Report

What are the key data covered in this HIV Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the HIV drugs market between 2023 and 2027
• Precise estimation of the size of the HIV drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the HIV drugs market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of HIV Drugs Market companies

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports

The Duchenne muscular dystrophy (DMD) therapeutics market is estimated to grow by USD 2,397.67 million at a CAGR of 21.2% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by type (biologics and small molecules), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The high unmet need among patients with Duchenne muscular dystrophy (DMD) is a key factor driving market growth during the forecast period.

The photodynamic therapy market is estimated to grow by USD 2,053.68 million at a CAGR of 8.22% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by application (cancer, actinic keratosis, psoriasis, acne, and others), product (photosensitizer drugs, and photodynamic therapy devices), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Early detection of cancer is a key factor driving market growth during the forecast period.

Table of Contents

Executive Summary

Market Landscape

Market Sizing

Historic Market Size

Five Forces Analysis

Market Segmentation by Distribution Channel

Market Segmentation by Therapy

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio